Biocardia, Inc.
Clinical trials sponsored by Biocardia, Inc., explained in plain language.
A biotech company developing cell-based therapies for cardiovascular disease.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Stem cell therapy for COVID-19 lung damage trial pulled before it began
Disease control TerminatedThis early-stage study aimed to test whether infusing donor stem cells could help people recover from acute respiratory distress syndrome (ARDS) caused by COVID-19. The trial was withdrawn before enrolling any participants, so no results are available. The approach was based on e…
Phase: PHASE1 • Sponsor: BioCardia, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could your own stem cells ease incurable chest pain?
Disease control OngoingThis trial tests whether injecting a patient's own bone marrow stem cells into the heart can improve exercise ability and reduce chest pain in people with severe, untreatable angina. About 343 participants will either receive the stem cell treatment or a sham procedure. The goal …
Phase: NA • Sponsor: BioCardia, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Stem cells injected into heart could ease failure
Disease control OngoingThis study tests if stem cells from donated bone marrow can help people with heart failure. The cells are delivered directly into the heart using a special catheter. The goal is to see if this treatment is safe and can improve heart function, reduce hospital stays, and help patie…
Phase: PHASE1, PHASE2 • Sponsor: BioCardia, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC